ArticleDiscover oncology2025
Unusual phenomenon in advanced hepatocellular carcinoma: declining alpha-fetoprotein levels despite disease progression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review of systemic therapy in HCC with an approach to response assessment in clinical practice.Abdominal radiology (New York) · 2026Review
- Long-Term Outcome of No-Touch Radiofrequency Ablation for Treating AFP-Positive Small Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In advanced hepatocellular carcinoma (HCC), some patients exhibit declining serum alpha-fetoprotein (AFP) levels despite disease progression. We investigated the characteristics, outcomes, and potential causes of this unusual phenomenon. We conducted a retrospective analysis of 139 patients with advanced HCC with baseline AFP ≥ 20 ng/mL, treated systemically and/or locally between March 2021 and May 2023. Patients were categorized into two groups: AFP abnormal trajectory group and AFP normal trajectory group. The ORR (0% vs. 18.8%, P = 0.037) and DCR (54.5% vs. 84.3%, P = 0.027) were significantly lower in the AFP abnormal group. The mPFS was 2.8 (95% CI: 1.34-4.25) months in the AFP abnormal group vs. 14.2 (95% CI: 10.57-17.82) months in the normal group (P < 0.001). The mOS was 14.0 (95% CI: 4.95-23.04) and 32.0 (95% CI: 16.4-47.5) months in the AFP abnormal and normal groups, respectively (P = 0.039). Combined targeted and immunotherapy (odds ratio [OR]: 15.35, 95% CI: 1.22-192.90, P = 0.034) and elevated neutrophil-to-lymphocyte ratio (OR: 1.29, 95% CI: 1.03-1.62, P = 0.025) were independent risk factors for abnormal AFP trajectories. A subset of patients with advanced HCC exhibit declining AFP levels despite disease progression, characterized by poor treatment response, accelerated progression, and poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.